Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells
Authors:
- 1 December 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (12) , 2819-2825
Abstract
Objective— The purpose of this study is to investigate the expression and regulation of type-2 tissue factor pathway inhibitor (TFPI-2) in endothelial cells, as well as the regulation of human endothelial cell (EC) function by TFPI-2. Methods and Results— Real-time polymerase chain reaction (PCR) and Western blot analysis revealed that vascular endothelial growth factor (VEGF) induced both time- and dose-dependent increase in TFPI-2 mRNA and protein expression in endothelial cells. TFPI-2 mRNA expression was also significantly upregulated by IL-1β, and modestly increased by both tumor necrosis factor (TNF)-α and fibroblast growth factor (FGF)-2, but not placental growth factor (PlGF). VEGF upregulation of TFPI-2 was dramatically reduced by inhibition of the MEK pathway. Administration of TFPI-2 protein suppressed both VEGF and FGF-2 stimulation of EC proliferation in a dose-dependent manner. A recombinant preparation of the first Kunitz-type domain of TFPI-2 (KD1) did not suppress growth factor stimulation of EC proliferation, suggesting a mechanism distinct from the proteinase inhibitory activity of TFPI-2. Exogenously added TFPI-2 protein suppressed VEGF-induced EC migration in 2 different assays. Recombinant wt-KD1 or the R24K mutant of KD1, but not the R24Q mutant, dramatically suppressed VEGF-induced EC migration. TFPI-2 protein, but not recombinant KD1, blocked VEGF-induced activation of both Akt and ERK1/2 in ECs. At higher doses, TFPI-2 protein blocked VEGFR2 activation. Conclusion— Our data suggest that VEGF-upregulation of TFPI-2 expression in endothelial cells may represent a mechanism for negative feedback regulation and modulation of its pro-angiogenic action on endothelial cells. TFPI-2, or derivatives of TFPI-2, may be novel therapeutics for treatment of angiogenic disease processes.Keywords
This publication has 27 references indexed in Scilit:
- Vasohibin is up‐regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularizationThe FASEB Journal, 2006
- Structure, function and biology of tissue factor pathway inhibitor-2Thrombosis and Haemostasis, 2005
- Structure-Function Analysis of the Reactive Site in the First Kunitz-type Domain of Human Tissue Factor Pathway Inhibitor-2Journal of Biological Chemistry, 2004
- The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic miceBlood, 2004
- Thrombin Up-regulates Tissue Factor Pathway Inhibitor-2 Synthesis through a Cyclooxygenase-2-dependent, Epidermal Growth Factor Receptor-independent MechanismJournal of Biological Chemistry, 2004
- Expression of tissue factor pathway inhibitor-2 in murine and human liver regulation during inflammationThrombosis and Haemostasis, 2004
- VEGF signalling: integration and multi-tasking in endothelial cell biologyBiochemical Society Transactions, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras ActivationJournal of Biological Chemistry, 2001
- Purification and characterization of placental protein 5Biochemical and Biophysical Research Communications, 1988